

2
Please replace paragraph at page 18, line 6, with:

AD

In preferred embodiments, R₅ is a hydrogen, or a halogenated lower alkyl.

Please replace paragraph at page 18, line 9, with:

A3

In preferred embodiments, R₆₁ and R₆₂, independently, represent lower alkyls, such as methyl, ethyl, propyl, isopropyl, tert-butyl or the like;

NB.
In the abstract:

On page 65, lines 1-7, please replace the abstract with the one presented on the following page:

JSC
9-27-2002

ABSTRACT OF THE DISCLOSURE

The present invention provides methods and compositions for modification and regulation of GLP 1 metabolism, glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis. The compositions described herein are high-affinity boronyl and non-boronyl peptidomimetic inhibitors of DPIV.

Q6